PARIS--(BUSINESS WIRE)-- Nanobiotix, the leading nanomedecine firm, Paris based, announces today that Laurent Condomine joins its Non Executive Board to help its growth.
“I am very pleased to join the Board of Nanobiotix. It is developing a portfolio of a new class of therapeutics that have the potential to transform cancer treatment. I am determined to help the company translate this breakthrough technology into value for patients, and for Nanobiotix Shareholders and its people” says Laurent Condomine. “I am impressed by the team and I look forward to working with its Management and with the Board, to release the impressive potential of its product portfolio.”
“We are proud to welcome Laurent Condomine, a passionate pharmaceutical executive who is going to play a key role in helping Nanobiotix growth. Laurent Condomine has all the qualities we were looking for to reinforce leading position in nanomedicine and make it fit into the pharma world. The focal point of his career has been pharma industry, and he has a clear understanding of small biotech companies requirements in terms of partnerships and development. He will collaborate side by side to our staff and board members“. Says Laurent Levy, CEO co-founder of Nanobiotix.
Laurent Condomine, has been VP Business Development of AstraZeneca in its HQ, based in London. He was in charge of developing the Corporate Strategy of the Group, and of delivering its external growth component. He previously held a similar position with ICI when he was involved in the demerger of this company in 1993, then with Zeneca where he played a key role in its merger with Astra in 1998. In 2007 he was a key member of the team in charge of the acquisition, by AstraZeneca, of MedImmune. He retired end of 2007. Prior to his move to London, he held managing positions, including CFO, Sales&Marketing Director and CEO, at ICI-Pharma (France). In 1989 he became CEO of ICI-France and joined the ICI Headquarters in London in 1992. Laurent Condomine graduated from HEC School of Management and holds a MBA from INSEAD. Laurent Condomine is non-executive Chairman of ExonHit, a publicly listed French biotech company.
“Laurent Condomine will bring a true value to Nanobiotix; that is the missing piece of our non executive board. Its operational experience as a senior executive in pharmaceutical industry would also be very supportive for the executive team.” Says Philippe Dhamelincourt; President; Matignon Investissement & Gestion.
About NanoXray Platform:
Radiotherapy is the second most common treatment in cancer therapy, used in more than 50% of all cancer patients. It is known to be an effective treatment, however the impact of its physical effect is limited by the dose of radiation that healthy tissues will stand, resulting in a narrow therapeutic window, and leaving a huge space for improvement. Nanobiotix has developed a new class of therapeutics based on nanoparticles, NanoXray™ therapeutics. They consist of inert nanoparticles designed to enter tumor cells. Upon activation by a standard dose of radiation, they release a tremendous amount of energy that destroys cancer cells, whilst the surrounding healthy tissues are preserved and receive the same dose of radiation as in standard radiotherapy. By significantly enhancing the power of radiotherapy, they could change the clinical outcome of radiotherapy and may also enable radiotherapy to play a larger role as a curative treatment.
ABOUT NANOBIOTIX - www.nanobiotix.com
Nanobiotix is a nanomedecine company dedicated to the development of new treatments for cancer based on the combined application of nanotechnologies and biotechnologies. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo that was incorporated in 2003 and has been primarily funded by leading European venture capital firms (Matignon Technologies, OTC Asset Management, Cap Decisif, Amorcage Rhone-Alpes, CIC Vizille; Masseran Gestion-CGE). With the development of numerous new compounds, Nanobiotix's objective is to increase its leading position in nanomedicine field.
KEYWORDS: Europe France
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical